Voveron 1ml causes Kidney Damage: Health Ministry panel recommends toxicity check for component Ruby Khatun Khatun5 Jan 2018 5:06 PM ISTNew Delhi: Trouble seems to be mounting for pharma giant Novartis after a panel from health ministry has raised concerns over the safety of diclofenac...
Gene therapy for rare form of blindness wins US approval Ruby Khatun Khatun21 Dec 2017 10:04 AM ISTWASHINGTON: U.S. health officials on Tuesday approved the nation's first gene therapy for an inherited disease, a treatment that improves the sight of...
Novartis generics arm says may sell or end some products Ruby Khatun Khatun18 Dec 2017 9:30 AM ISTZURICH: Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on...
4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe Ruby Khatun Khatun15 Dec 2017 5:15 PM ISTMumbai: Trouble is mounting for 4 big pharma companies over price fixing of an anti-diabetic drug. An investigation has initiated on drug makers...
Novartis CAR-T therapy leads to durable response in lymphoma study Ruby Khatun Khatun11 Dec 2017 10:45 AM ISTPatients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy...
Pfizer, Novartis agree UK price cuts for new breast cancer drugs Ruby Khatun Khatun17 Nov 2017 9:45 AM ISTLONDON: Pfizer and Novartis have agreed to price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely...
Novartis posts eye drug data amid play for Eylea's turf Ruby Khatun Khatun14 Nov 2017 9:45 AM ISTZURICH: Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new...
Novartis takes fight to Pfizers Ibrance with new Kisqali data Ruby Khatun Khatun10 Nov 2017 10:17 AM ISTZURICH: New data from Novartis's breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid...
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries Ruby Khatun Khatun25 Sept 2017 9:21 AM ISTBasel: Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current...
Novartis Rydapt wins EU approval for AML, other diseases Ruby Khatun Khatun22 Sept 2017 9:57 AM ISTZURICH: Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML)...
Novartis Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data Ruby Khatun Khatun21 Sept 2017 9:57 AM ISTBasel, September 13, 2017 - Novartis announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin...
Novartis posts a win, Roche a flop in skin cancer trials Ruby Khatun Khatun12 Sept 2017 12:30 PM ISTZURICH/MADRID: Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche...
